419 related articles for article (PubMed ID: 20881957)
21. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
22. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
23. A demand for next-generation oncolytic adenoviruses.
Hermiston T
Curr Opin Mol Ther; 2006 Aug; 8(4):322-30. PubMed ID: 16955695
[TBL] [Abstract][Full Text] [Related]
24. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
25. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
27. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T
Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013
[TBL] [Abstract][Full Text] [Related]
28. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.
Ong HT; Federspiel MJ; Guo CM; Ooi LL; Russell SJ; Peng KW; Hui KM
J Hepatol; 2013 Nov; 59(5):999-1006. PubMed ID: 23867315
[TBL] [Abstract][Full Text] [Related]
29. Attenuated oncolytic measles virus strains as cancer therapeutics.
Msaouel P; Iankov ID; Dispenzieri A; Galanis E
Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic viruses move forward in clinical trials.
Rowan K
J Natl Cancer Inst; 2010 May; 102(9):590-5. PubMed ID: 20421567
[No Abstract] [Full Text] [Related]
31. Oncolytic virotherapy for cancer treatment: challenges and solutions.
Davis JJ; Fang B
J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
[TBL] [Abstract][Full Text] [Related]
32. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
[TBL] [Abstract][Full Text] [Related]
33. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
[TBL] [Abstract][Full Text] [Related]
34. Vesicular stomatitis virus: re-inventing the bullet.
Lichty BD; Power AT; Stojdl DF; Bell JC
Trends Mol Med; 2004 May; 10(5):210-6. PubMed ID: 15121047
[TBL] [Abstract][Full Text] [Related]
35. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus.
Yoo JY; Ryu J; Gao R; Yaguchi T; Kaul SC; Wadhwa R; Yun CO
J Gene Med; 2010 Jul; 12(7):586-95. PubMed ID: 20603860
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
[TBL] [Abstract][Full Text] [Related]
37. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic-adenovirus-expressed RNA interference for cancer therapy.
Pei DS; Di JH; Chen FF; Zheng JN
Expert Opin Biol Ther; 2010 Sep; 10(9):1331-41. PubMed ID: 20684738
[TBL] [Abstract][Full Text] [Related]
39. Optimization of virotherapy for cancer.
Biesecker M; Kimn JH; Lu H; Dingli D; Bajzer Z
Bull Math Biol; 2010 Feb; 72(2):469-89. PubMed ID: 19787406
[TBL] [Abstract][Full Text] [Related]
40. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
